Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series
- Poster presentation
- Open Access
Toward the identification of genetic determinants of breast cancer immune responsiveness
Journal for ImmunoTherapy of Cancer volume 3, Article number: P1 (2015)
Overlapping immune signatures are observed among cancers with a better prognostic connotation and those with an increased likelihood to respond to immunotherapeutic approaches [1, 2]. Such signatures qualitatively overlap with those detected during other conditions of immune-mediated tissue destruction such as flares of autoimmunity or allograft rejection . These pathways reflect a process characterized by the coordinated activation of interferon stimulated genes (ISGs), the recruitment of cytotoxic cells through the production of specific chemokine ligands (CXCR3 and CCR5 ligands), and the activation of immune effector function (IEF) genes . We refer to these genes as the Immunologic Constant of Rejection (ICR) [2–4]. Here, we tested up-front the prognostic role of the ICR genes in the TCGA (The Cancer Genome Atlas) breast cancer database. We show that ICR genes can segregate breast cancers in different immune phenotypes characterized by distinctive prognostic connotations. Whether the favorable cancer immune phenotype is driven by the intrinsic genetics of the tumor cells is presently unknown. By mining copy number variation, gene-expression, and exome sequencing data we are currently characterizing breast cancer somatic alterations implicated in the development of this favorable cancer immune phenotype. The results of this analysis will be presented and discussed.
Bedognetti D., Spivey T. L., Zhao Y., Uccellini L., Tomei S., Dudley M. E., Ascierto M. L., De Giorgi V., Liu Q., Delogu L. G., Sommariva M., Sertoli M. R., Simon R., Wang E., Rosenberg S. A., Marincola F. M.: CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British journal of cancer. 2013, 109 (9): 2412-23. 10.1038/bjc.2013.557.
Galon J., Angell H. K., Bedognetti D., Marincola F. M.: The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity. 2013, 39 (1): 11-26. 10.1016/j.immuni.2013.07.008.
Spivey T. L., Uccellini L., Ascierto M. L., Zoppoli G., De Giorgi V., Delogu L. G., Engle A. M., Thomas J. M., Wang E., Marincola F. M., Bedognetti D.: Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med. 2011, 9: 174-10.1186/1479-5876-9-174.
Wang E., Bedognetti D., Marincola F. M.: Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. J Clin Oncol. 2013, 31 (19): 2369-2371. 10.1200/JCO.2013.49.2157.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Simeone, I., Hendrickx, W., Miller, L. et al. Toward the identification of genetic determinants of breast cancer immune responsiveness. j. immunotherapy cancer 3 (Suppl 1), P1 (2015). https://doi.org/10.1186/2051-1426-3-S1-P1
- Breast Cancer
- Copy Number Variation
- Exome Sequencing
- Immunotherapeutic Approach
- Interferon Stimulate Gene